pubmed-article:16572419 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:16572419 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
pubmed-article:16572419 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
pubmed-article:16572419 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
pubmed-article:16572419 | lifeskim:mentions | umls-concept:C0553580 | lld:lifeskim |
pubmed-article:16572419 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
pubmed-article:16572419 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
pubmed-article:16572419 | lifeskim:mentions | umls-concept:C0020823 | lld:lifeskim |
pubmed-article:16572419 | lifeskim:mentions | umls-concept:C0042679 | lld:lifeskim |
pubmed-article:16572419 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
pubmed-article:16572419 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
pubmed-article:16572419 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:16572419 | pubmed:dateCreated | 2006-5-8 | lld:pubmed |
pubmed-article:16572419 | pubmed:abstractText | The EUROpean Ewing tumour Working Initiative of National Groups 1999 (EURO-E.W.I.N.G. 99) protocol prescribes six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) as intensive induction chemotherapy for Ewing tumors (ET). Granulocyte-colony stimulating factor (G-CSF) is recommended. Adverse reactions (AR) were evaluated; quality assurance of data collection reviewed. | lld:pubmed |
pubmed-article:16572419 | pubmed:language | eng | lld:pubmed |
pubmed-article:16572419 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16572419 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:16572419 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16572419 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16572419 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16572419 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16572419 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:16572419 | pubmed:month | Jul | lld:pubmed |
pubmed-article:16572419 | pubmed:issn | 1545-5009 | lld:pubmed |
pubmed-article:16572419 | pubmed:author | pubmed-author:ZoubekAndreas... | lld:pubmed |
pubmed-article:16572419 | pubmed:author | pubmed-author:LewisIanI | lld:pubmed |
pubmed-article:16572419 | pubmed:author | pubmed-author:PaulussenMich... | lld:pubmed |
pubmed-article:16572419 | pubmed:author | pubmed-author:MichonJeanJ | lld:pubmed |
pubmed-article:16572419 | pubmed:author | pubmed-author:OberlinOdileO | lld:pubmed |
pubmed-article:16572419 | pubmed:author | pubmed-author:WestonClaireC | lld:pubmed |
pubmed-article:16572419 | pubmed:author | pubmed-author:CraftAlanA | lld:pubmed |
pubmed-article:16572419 | pubmed:author | pubmed-author:JuergensHerbe... | lld:pubmed |
pubmed-article:16572419 | pubmed:author | pubmed-author:WhelanJeremyJ | lld:pubmed |
pubmed-article:16572419 | pubmed:author | pubmed-author:JuergensChris... | lld:pubmed |
pubmed-article:16572419 | pubmed:copyrightInfo | Copyright 2006 Wiley-Liss, Inc. | lld:pubmed |
pubmed-article:16572419 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:16572419 | pubmed:volume | 47 | lld:pubmed |
pubmed-article:16572419 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:16572419 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:16572419 | pubmed:pagination | 22-9 | lld:pubmed |
pubmed-article:16572419 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:meshHeading | pubmed-meshheading:16572419... | lld:pubmed |
pubmed-article:16572419 | pubmed:year | 2006 | lld:pubmed |
pubmed-article:16572419 | pubmed:articleTitle | Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. | lld:pubmed |
pubmed-article:16572419 | pubmed:affiliation | Coordinating Centre for Clinical Trials (KKS), University of Muenster, Muenster, Germany. | lld:pubmed |
pubmed-article:16572419 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:16572419 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:16572419 | pubmed:publicationType | Multicenter Study | lld:pubmed |
pubmed-article:16572419 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16572419 | lld:pubmed |